New and improved vaccines: Promising weapons against varicella, hepatitis A, and typhoid fever

Postgraduate Medicine

Volumn 100, Issue 4, 1996, Pages

  Conrad, Dennis A ^b   Jenson, Hal B ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; HEPATITIS A VACCINE; MEASLES MUMPS RUBELLA VACCINE; SALICYLIC ACID DERIVATIVE; TYPHOID VACCINE;

BIOTECHNOLOGY; CHICKENPOX; DEVELOPING COUNTRY; DRUG CONTRAINDICATION; DRUG INDICATION; ERYTHEMA; FEVER; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEPATITIS A; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; MALAISE; ORAL DRUG ADMINISTRATION; PREGNANCY; RASH; REVIEW; SALMONELLA TYPHI; SUBCUTANEOUS DRUG ADMINISTRATION; TRAVEL; TYPHOID FEVER; VACCINE PRODUCTION;

EID: 10244240625     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1996.10.95     Document Type: Review

References (20)

1. Drwal-Klein LA, O'Donovan CA. Varicella in pediatric patients. Ann Pharmacother 1993; 27(7-8):938-49
2. White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 1992;11(1):19-23
3. Gershon AA. Varicella vaccine. Isr J Med Sci 1994;30(5-6):482-4
4. Gershon AA, LaRussa P, Hardy I, et al. Varicella vaccine: the American experience. J Infect Dis 1992;166(Suppl 1):S63-8
5. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994;271(5): 375-81
6. Balcarek KB, Bagley MR, Pass RF, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children. J Infect Dis 1995;171(Suppl 1):S70-2
7. Sandman L, Davidson M, Krugman S. Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals. J Infect Dis 1995;171(Suppl 1):S50-2
8. Nalin DR, Kuter BJ, Brown L, et al. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J Hepatol 1993;18(Suppl 2):S51-5
9. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271(17):1328-34
10. Clemens R, Safary A, Hepburn A, et al. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995;171(Suppl 1):S44-9
11. Centers for Disease Control and Prevention. Hepatitis A among persons with hemophilia who received clotting factor concentrate: United States, September-December 1995. MMWR 1996;45(2):29-32
12. Centers for Disease Control and Prevention. Licensure of inactivated hepatitis A vaccine and recommendations for use among international travelers. MMWR 1995;44(29): 559-60
13. La Brooy JT. Typhoid in 1993. Med J Aust 1993;159(9):598-601
14. Shepard DS, Walsh JA, Kleinau E, et al. Setting priorities for the Children's Vaccine Initiative: a cost-effectiveness approach. Vaccine 1995;13(8):707-14
15. Centers for Disease Control and Prevention. Typhoid immunization. MMWR 1994; 43(RR-14):1-7
16. Plotkin SA, Bouveret-Le Cam N. A new typhoid vaccine composed of the vi capsular polysaccharide. Arch Intern Med 1995;155: 2293-9
17. Hall CB. A single shot at Salmonella typhi: a new typhoid vaccine with pediatric advantages. Pediatrics 1995;96(2 Pt 1):348-50
18. Simanjuntak CH, Paleologo FP, Punjabi NH, et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991;338(8774):1055-9
19. Levine MM, Ferreccio C, Black RE, et al. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987;1(8541):1049-52
20. Cumberland NS, St Clair Roberts J, Arnold WS, et al. Typhoid Vi: a less reactogenic vaccine. J Int Med Res 1992;20(3):247-53